Destiny Pharma plc (LON:DEST), only the second biotech float this year, is bringing through a next-generation antibiotic.
Chief executive Neil Clark tells Proactive The bulk of the £15mln they raised will go towards funding a phase IIb clinical trial on XF-73 for the prevention of post-surgical staphylococcus aureus infections, including the deadly MRSA.
Price: 115.5 GBX
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Destiny Pharma PLC named herein, including the promotion by the Company of Destiny Pharma PLC in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HERE
Destiny Pharma's (LON:DES) Neil Clark (CEO) pitches to investors at the Proactive One2One live virtual forum. Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its...
Tech
